Risk Factors for Artificial Kidney Failure During Continuous Renal Replacement Therapy

  • Wen Guo Emergency Department, The First Affiliated Hospital of Chongqing Medical University
  • Xuemei Chen Emergency Department, The First Affiliated Hospital of Chongqing Medical University
DOI: https://doi.org/10.18686/aem.v12i2.377
Keywords: Continuous Renal Replacement Therapy, Artificial Kidney Failure, Access Outflow Dysfunction

Abstract

Objective To explore the influencing factors of artificial kidney failure (AKF) during continuous renal replacement therapy (CRRT). Methods We conducted a retrospective observational study on 70 patients undergoing 199740 minutes of CRRT comprising 143 circuits at the Department of Intensive Care Medicine of First Affiliated Hospital of Chongqing Medical University from August 2021 to August 2022. Results The occurrence rate and total time of access outflow dysfunction (AOD) in AKF group increased significantly than those in nAKF group. Receiver Operating Characteristic (ROC) Curve analysis showed the optimal cutoff value of AOD total time (AODTT) was 7 minutes. Logistic regression analysis further showed that AODTT≥7 min was an independent predictor of AKF. Conclusion The presence of AOD was related to AKF. AODTT≥7 min during CRRT was an independent risk factor for AKF.

References

[1] Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002; 346(5): 305-310.
[2] Neyra JA, Tolwani A. CRRT prescription and delivery of dose. Semin Dial. 2021; 34(6):432-439.

[3] Zhang L, Tanaka A, Zhu G, et al. Patterns and Mechanisms of Artificial Kidney Failure during Continuous Renal Replacement Therapy. Blood Purif. 2016; 41(4): 254-263.

[4] Gattas DJ, Rajbhandari D, Bradford C, et al. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine 2015;43(8):1622-9.

[5] Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020;3(3):CD012467.

[6] Tsujimoto Y, Miki S, Shimada H, et al. Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2021;9(9):CD013330.

[7] Zhang L, Baldwin I, Zhu G, et al. Automated electronic monitoring of circuit pressures during continuous renal replacement therapy: a technical report. Crit Care Resusc. 2015;17(1):51-54.

[8] Michel T, Ksouri H, Schneider AG. Continuous renal replacement therapy: understanding circuit hemodynamics to improve therapy adequacy. Curr Opin Crit Care. 2018; 24(6): 455-462.

[9] Li P, Zhang L, Lin L, et al. Effect of Dynamic Circuit Pressures Monitoring on the Lifespan of Extracorporeal Circuit and the Efficiency of Solute Removal During Continuous Renal Replacement Therapy. Front Med (Lausanne). 2021;8:621921.

[10] Sansom B, Sriram S, Presneill J, et al. Circuit Hemodynamics and Circuit Failure During Continuous Renal Replacement Therapy. Crit Care Med. 2019; 47(11): e872- e879.

[11] Tandukar S, Palevsky PM. Continuous Renal Replacement Therapy: Who, When, Why, and How. Chest. 2019;155(3):626-638.

[12] Kim IB, Fealy N, Baldwin I, et al. Premature circuit clotting due to likely mechanical failure during continuous renal replacement therapy. Blood Purif. 2010; 30(2): 79-83.

[13] Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med. 2004;30(11):2074-2079.

[14] Mann L, Ten Eyck P, Wu C, et al. CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial. PLoS One. 2023; 18(1): e0278550.

[15] Davies HT, Leslie G, Pereira SM, et al. A randomized comparative crossover study to assess the affect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. Int J Artif Organs. 2008; 31(3):221–7.

[16] Poh CB, Tan PC, Kam JW, et al. Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy - A Safe and Effective Low-Dose Protocol. Nephrology (Carlton). 2020; 25(4):305-313.

[17] Crosswell A, Brain MJ, Roodenburg O. Vascular access site influences circuit life in continuous renal replacement therapy. Crit Care Resusc. 2014;16(2):127-130.

[18] Parienti JJ, Mégarbane B, Fischer MO, et al. Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med. 2010; 38(4): 1118-1125.
Published
2023-06-01
Issue
Vol 12, No 2 (2023)
Section
Original Research Article

Copyright (c) 2023 Wen Guo, Xuemei Chen

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.